ProCE Banner Activity

Real-world Multicenter Retrospective Study of Idecabtagene Vicleucel in Patients With R/R MM After Previous BCMA-Targeted Therapy Exposure

Slideset Download

Patients who received idecabtagene vicleucel after previous BCMA-targeted therapy have high response rates but worse overall outcomes compared with patients who have not received previous BCMA-targeted therapy.

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen